- The P-IV HER-MES study involves assessing Aimovig (erenumab 70mg and 140mg) vs topiramate in 777 patients in a ratio (1:1) with episodic or chronic migraine (≥4 migraine days/month) prior not treated with migraine prevention treatment or previously failed up to three prophylactic migraine treatments
- The study met its 1EPs & 2EPs and had superior tolerability against topiramate, with a higher proportion of patients remaining on Aimovig than on topiramate. The therapy showed superior efficacy, with a greater proportion of patients achieving at least a 50% reduction in their MMDs
- Aimovig is the first EMA, Swissmedic, and US FDA’s approved migraine prevention treatment designed to target CGRP-R
Click here to read the full press release/ article | Ref: GlobeNewswire | Image: Caixin Global
The post Novartis Reports Results of Aimovig (erenumab) in P-lV Study for Episodic and Chronic Migraine first appeared on PharmaShots.